Currently, we provide antiviral screening of compounds prepared in the institute against viruses listed below. For active compounds we provide also cytotoxicity measurements in cell line(s) used for the particular antiviral screening.


  • ssRNA-RT
      - Human immunodeficiency virus type 1 (HIV-1) in MT-4 cells
  • +ssRNA
      - Coxsackie B3 virus in HeLa cells
      - Dengue type 2 virus in Vero cells
  • -ssRNA
      - Influenza A in MDCK cells


  • Herpes simplex type 1 virus (HSV-1) in Vero cells

Service additions in near future

Hepatitis B virus (summer 2014)

Instructions for compounds screening request

Preferentially the requester will add their compounds into IOCB compound library. This procedure will guarantee the testing of the compounds against all viruses currently used in the screening. For special requests contact Jan Weber.

In addition, we are able to perform custom made experiments involving BSL3 and BSL2 pathogens (virus isolation and culturing, fluorescence immunochemistry techniques, ELISA, western blots, reverse transcriptase activity assays). We welcome any suggestions, comments and questions.

Completed/ongoing service projects for reference

  • Benzo-fused 7-deazaadenosine analogoues tested against Dengue type 2 virus (Dr. Michal Hocek, IOCB AS CR, v.v.i.)
  • Benzoxazine derivatives active against multidrug resistant tuberculosis (MDR-TB) strains tested against HIV-1 (Dr. Eva Novotná, Faculty of Pharmacy in Hradec Králové)
  • Carboranes analogues tested against HIV-1 (Dr. Jan Konvalinka, IOCB AS CR, v.v.i.)
  • Novel purine analogues as PI4KIII? inhibitors tested against Coxsackie B3 virus (Dr. Radim Nencka, IOCB AS CR, v.v.i.)
  • Cyclopentane derivatives tested against Dengue type 2 virus (Dr. Ullrich Jahn, IOCB AS CR, v.v.i.)
  • Nanocomposite hybrid coating tested against HIV-1, dengue type 2 virus, herpes simplex virus 1, coxsackie B3 virus and influenza A (prof. Ivan Stibor, Technical University of Liberec)